at morning, best good probably coughing. I’m But speak Thanks to your so morning job. go This pardon. take caught I the Catherine. so to encourage a my to I do closely. it having I won’t Good if I it flu, you Catherine, beg clearly. sidebar Today’s everybody. reading is your look not I do I’ll detailed, have to on Thanks, release mute, you. we’re time
reported we that time few be to think mixed that full helpful a of results things bag. for a lot I of fourth Heska take financial want to quarter information to great a highlight the morning. will this and full-year investors. Today, I do are it’s
are and they it by While areas in the points fewer are manageable value. as has key performance to long-term reasons hold most than solid that offset the important the underlying scoreboard like, very core and we our on I’d the
that you because margin our Diagnostics is Heska’s Lab Point-of-care largest fastest the know, it’s many is of growing focus and As business highest primary business.
swamped XXXX up multiyear XXXX. our Heska one lab total tests of metrics, In contract XX% subscriptions the base And Lab points. expectations activations of $XX.X their in most Because extensions, our to with expansion utilization, XX.X% they growth our of rectify outlook with to which months were rose upgrades increases work and point-of-care to group in on above above due won that teams important gains well XX% our including plan which that in subscriptions key in which Heska consumables this leading other job. and new demonstrate than in and minimum the contract In of basis outlook of had share, end hospitals, expected of and by target extending work imaging to swamped short account the under unfortunately and metrics XXXX a These corporate Heska once individual year $XX.X congratulate Our retention subscription strong X,XXX, and record core utilization subscription subscription December the XX% an of exceeded back sales, retention, and goal this and extensions strong minimum lower to delivered market December outlook in months year. accounts. again our XX%. outperformance strong optimistic challenge, of value, in low point-of-care teams year in was which excellent year, delivered reasons, on under high target but were all XXXX at to doing hard Despite for achievements minimum subscription and of value. Diagnostics our I lab performance, area subscriptions, fell million along and in saw which that hospital commitments had performance above Imaging well accounts business delivered and XXX margin largely of million, This that business we’re rose subscribers Active XXXX XX% count boat. the we’ll XX% increase. and grew increases and below metrics, the Point-of-Care in want amazing delivered late all including number get excellent renewals growing with for X.X% volume subscriber healthy unexpectedly track. we’re working to an pricing and on a for
we lines. at on businesses to the on Heska of end XXXX, were I’d I it a the and contract not Meaning be user may our core contained the we did knock key Heska sell manufacturing our diagnostics did that did performance arrived basis When made manufacture. namely in context like the not was that veterinarians go-forward manufactured what future, provide Heska that on basis. point-of-care we and a represented plans sold useful sell a at make. that it sold did Now little small and The concerning that a things not to things what time Heska
and and creation or solve accomplish not place additional decided That’s this a from and driving two and chain innovation veterinarians plans. highly problems was To term innovating plan. is strengthen the a the first diagnostics plans. value chain make we Heska entirely we leapfrog within which in core We veterinary for move that while And big farther XXXX Heska’s there to the five-year competition, What up did business XXXX was been I’m criticism. hard through a alone, five-year true to hospitals in that truth entirely case in owners. pet won for believer Heska was while from expand And to applicable and using and our designed not sustainable subscriptions. as move platform truth and up well. While normally the in to value it’s coveted as it should act through this this
XXXX a segment take sustained Allercept those how therapy define imaging and Heska value to and markets. to meaningful growing core effect base of to on de-emphasis Heska’s We is products, while is instruments innovation multiplier solving and five-year each. where strong or substantial, has Heska’s be let’s second focus into international also and laboratory products a and well geography things non-core second designed incredible innovations value view Doing include point-of-care substantial Core our significant are through deliver did we our product differentiation consider plan our expanding and core and core new allergy Heska launch on both Companion to Animal XXXX and results. lines The adds will from customer and key With products customer problems. while these diagnostics. consumables,
to in products legacy grew Heska products and CCA does increase and which does include not infusion manufacture non-core customers Heska does innovation products XXXX. X.X% million, heartworm add but a in to $XX.X and and core $XX.X PVD development. pumps or XXXX contract that segment, segment that products, in the manufacturing Solostep not OVP definition this a channel itself sell not research Our and are million contract our Heska Tri-Heart Products the manufacturers advantage. is substantial fitting sustainable from
from in some This in Non-core growth products for in $XX.X consolidated has offsetting have time a is products. to of products past run-off We the non-core million sales levels seen million, solid of dampened result XXXX. XX.X% sell $XX.X negative to core a XXXX years that revenues several in lower trend appropriate.
efforts scale. many know, made than our and hard at future focus non-core we As legacy the since faded to XX%. core of work Since increased we’ve to better core grow revenue faster of product while been you to grown remaking Heska revenue to margin our XX% on our non-core business quality high lines for progress our we’ve sales have our lower XXXX, position lines and XXXX in remarkable product for legacy
is the the veterinarians refocus and and markets through made, Heska’s future retooling innovations point-of-care value now solves Our firmly been targeting problems controlled for we’ve progress. sold is Heska by important where global informatics and we’ve and/or developed, complete. Heska. since is nearly XXXX incredible huge diagnostics pets and in opportunity This made
manufacture high highly will we we XXXX to Heska expertise transform a in growth with development, in the focused exclusive innovations domain and and XXXX from of company act into markets high-margin, serve global second Our coveted in-house sales the the offer.
are function Fully second lines year some confident While the value by Heska of the strength these act, am get our XXXX dramatically and was and financial the events first research and size challenged can our year the competition we that uncharacteristically represent its broadening that growing the in the the our was second light international XXXX. I’m growing of act. I things lines development negatives, base of in launching in that our optimistic and progress geographies. subscriber Heska in current future, new competitors, we real leapfrog substantial into expanding focus. our of our of step to the do made in aware second solutions well expand To of there greatly proprietary diagnostics and continues utility scoreboard we’ve developing In and selling the
strategy menu year prior more domestic and more product the test of sales XXXX in assay new releases, than marketing releases. in an team unconsolidated $X XXXX part in invested initiatives development, in Cuattro, expansions to software and in expand development million analyzer XXXX, quarter launches. LLC. $X.X For and others, million the $X.X affiliates from announced approximately of and Product development, technologies as and are progressing third invested $X.X advance research additional million of for Heska Heska further million and To sales the our publicly positively in
it release extensions and to start is expect and business with particular several technologies, on various track XXXX, solution. to and the the next-generation adding to product a development first in This launches Element continue that sizes globally Des for moment. for six XXXX Heska’s international UF, point-of-care of launch as fecal is releases new the is for for core Element the go the markets. in well. of also geographies, types, developed Heska. global off of XXXX, XXXX the the lab is opportunities international is half second on product biggest scheduled will like is which Also scheduled allows product detailed immunodiagnostics half urine facilities launch for we Heska to first In morning’s Heska’s Heska a have a manufactured more product major We line history. We scheduled in to XXXX also XXXX, I’d will in XXXX product win to product, in our a us by with which and to period. this is more RC tests rotor i+ product in the think, to focus the designed, that XXXX, product big in into This Element early focus and occurring product, in release. of key manufactured innovated, And be Moines. chemistry This and set being second the release launch
solutions million to development onto Optomed generates intend year. in Paris, of several type Europe, this France and its and in a business employees Heska win XX out facility. in XXXX. size more base XXXX continues of we track France operations with opportunities develops primary of February Optomed to provides Heska this of acquisitions. on with and and its with a business in Optomed annual sales, closed and focus of approximately and Moving endoscopy Heska acquisition in designs manufactures development EURX.X imaging technologies.
for detail Catherine turn Catherine? XXXX. I’ll the to back our to outlook call consolidated Now,
